Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (2679)	8/9/2006 3:08:34 PM
From: Ian@SI	of 3044

A somewhat weird abstract... ... a new irreversible proteasome inhibitor (NPI-0052) on 20S chymotryptic proteasome activity and apoptosis in isolated CLL cells in vitro ... Our results show that NPI-0052 is a more effective proapoptotic agent than bortezomib in isolated CLL cells Then without any claims about safety or efficacy in animals, it goes on to say, "Based on its in vitro and animal data, Nereus hopes to file an investigational new drug application..." This makes me suspect that the animal data didn't exist at the time the article was published. I'll probably google it and see if anything pops up or whether this molecule has undergone apoptosis. ;-) Personally I'd be very concerned about systemic delivery of an irreversible toxin. Ian

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next